Physician profile
Robert W Moore
NPI 1013906957
$233.18
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.86 · 2020: $35.82 · 2021: $49.55 · 2022: $65.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $91.38 | 2019-2022 | |
| Abbvie INC. | $40.79 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.00 | 2019 | |
| Abbott Laboratories | $22.83 | 2022 | |
| Merck Sharp & Dohme LLC | $15.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.65 | 2019 | |
| Sanofi Pasteur INC. | $12.03 | 2019 | |
| Novo Nordisk INC | $11.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.